CelerisTx Reels in Another Big Partner in Boehringer Ingelheim

BioSpace® – April 05, 2022

Celeris Therapeutics and Boehringer Ingelheim (BI) have announced they are entering into a collaboration to develop next-generation targeted protein degraders.

CelerisTx Appoints Pharmaceuticals Industry Leader Peter Ho, M.D., Ph.D., to the Board of Directors

BioSpace® – February 25, 2022

CelerisTx, the pioneer in AI-driven proximity-inducing compound discovery, today announced the appointment of Peter T.C. Ho, M.D., Ph.D., to the Board of Directors.

CelerisTx announces $4.4m financing to advance pipeline of novel proximity inducing compound

BioSpace® – February 10, 2022

Celeris Therapeutics, the PIC™ engineering company, announces the closing of their $4.4m USD Series Seed Financing round.

Merck KGaA enlists little AI player on protein degrader discovery

Endpts – February 09, 2022

The German pharma has tapped CelerisTx, a Menlo Park, CA-based biotech with roots in Austria, and its artificial intelligence platform for two drug discovery projects. The main goal, according to the companies, is to identify active small molecule binders.

CelerisTx in Artificial Intelligence research collaboration with Merck KGaA, Darmstadt, Germany on AI-enabled degrader discovery

BioSpace® – February 09, 2022

Collaboration enables Merck KGaA, Darmstadt, Germany access to CelerisTx AI platform across two drug discovery projects

Celeris Therapeutics, the PIC™ engineering company, announces the appointment of biotech veterans to lead drug discovery and biology efforts

BioSpace® – February 02, 2022

The hirings of Dr. Friedrich Kroll, who is joining as VP Drug Discovery, and Dr. Markus Muellner joining as VP Biology, reflect the ambition to get into the clinic fast.

Celeris Therapeutics, Inc., pioneering AI-driven degrader discovery, appoints Nick DeHaan as VP, Head of Partnering

EINPresswire – November 29, 2021

Silicon Valley-based startup recruits experienced business development leader to drive growth in AI-based protein degrader discovery partnerships

Celeris Therapeutics, the Pioneer in AI-driven Degrader Design, Builds Laboratories in Austria

EINPresswire – November 01, 2021

Adds ~25 new jobs, building on 20 created in 2021. Increases capacity and efficiency of AI-based drug discovery capabilities in chemistry and biology.

Celeris Therapeutics Welcomes Life Sciences and Technology Thought Leader Ian Marks as a Non-Executive Director

EINPresswire – August 27, 2021

Global VP of Life Sciences at Salesforce contributes a great deal of experience in life sciences, pharma and technology

Rational design for protein degradation? Austrian deep learning startup takes a stab

Endpoints – July 19, 2021

Rational design for protein degradation? Austrian deep learning startup takes a stab

600.000 Euro für Grazer Startup Celeris

Der Brutkasten – May 3, 2021

Knapp nach einem 400.000 Euro Seed-Investment holt sich Celeris aus Graz eine aws-Förderung für seine Medikamentenforschungstechnologie.

Cutting longevity drugs development from 15 years to on

Noah Weber – March 31, 2021

Celeris bags €400k for creation of deep learning platform to support development of longevity drugs for Alzheimer’s and other age-related diseases.

Accelerating drug discovery through artificial intelligence would help to bring longevity innovations to the clinic more quickly. – April 06, 2021

We all know that technology is rapidly improving and changing how we live. But we’re going to need even more technological breakthroughs to improve human maximum healthspan and lifespan. Can a new start-up cut longevity drugs development from 15 years to one?

Grazer Biotech-Startup erhält 400.000 Euro Pre-Seed-Investment

Der Brutkasten – March 31, 2021

Celeris Therapeutics will mit seiner Plattform ermöglichen, dass bessere Medikamente schneller auf den Markt kommen – und konnte damit internationale Investoren überzeugen.

Durch künstliche Intelligenz zum perfekten Medikament

CHEManager – January 26, 2021

Eine Deep-Learning-Plattform für medizinische Chemiker zur schnelleren und genaueren Vorhersage von Bindungsaffinitäten und daraus resultierendem Design von Arzneimitteln – das will das Start-up Celeris Therapeutics aus Graz noch dieses Jahr zur Marktreife entwickeln.